Menu
Other Tablet

Lithostat

250 mg

Active Ingredient
Acetohydroxamic Acid
Estimated Price
Not specified

Potent urease inhibitor. Used adjunctively in chronic urea-splitting urinary tract infections to halt the growth of Struvite (staghorn) stones. High rate of intolerable side effects (phlebitis, deep vein thrombosis, tremulousness).

Author Profile Picture
Medically Reviewed By
Dr. Amro Algoshae
prominent physician, expert, and consultant in the fields of pharmaceutical marketing, healthcare marketing, and medical facilities management in Yemen.
Medical Disclaimer The information provided in this comprehensive guide is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with your physician before taking any new medication.

Comprehensive Overview of Lithostat (Acetohydroxamic Acid)

Lithostat, known generically as acetohydroxamic acid (AHA), is a specialized pharmaceutical agent primarily utilized in the management of chronic urea-splitting urinary tract infections (UTIs). Unlike traditional antibiotics that aim to kill bacteria, Lithostat functions as a potent urease inhibitor. By preventing the breakdown of urea into ammonia, it effectively modifies the chemical environment of the urinary tract, thereby inhibiting the formation of struvite (magnesium ammonium phosphate) calculi.

In the field of urology and nephrology, Lithostat serves as a critical adjunct therapy for patients who are not candidates for surgery or for whom surgical removal of stones is insufficient to prevent recurrence. This guide provides an exhaustive clinical overview of its pharmacological profile, administration, and safety parameters.


Technical Specifications and Mechanism of Action

The Urease Inhibition Pathway

The primary clinical utility of Lithostat lies in its ability to inhibit the bacterial enzyme urease. Urease is produced by various pathogens, most notably Proteus mirabilis, Klebsiella, and Pseudomonas species. Under normal physiological conditions, these bacteria hydrolyze urea in the urine into ammonia and carbon dioxide.

The resulting ammonia increases the pH of the urine, creating an alkaline environment that reduces the solubility of magnesium and phosphate ions. This chemical shift leads to the precipitation of struvite crystals, which form the matrix of staghorn calculi.

Pharmacokinetics

Understanding the pharmacokinetic profile of Lithostat is essential for maintaining therapeutic efficacy while minimizing systemic side effects.

Parameter Clinical Characteristic
Absorption Rapidly absorbed from the gastrointestinal tract.
Peak Plasma Concentration Reached within 30 to 60 minutes post-ingestion.
Distribution Widely distributed in body tissues; crosses the blood-brain barrier.
Metabolism Partially metabolized to acetamide; significant excretion remains unchanged.
Half-Life Approximately 5 to 10 hours in patients with normal renal function.
Excretion Primarily renal (50-60% excreted unchanged in urine).

Clinical Indications and Usage

Lithostat is not a first-line antibiotic. It is specifically indicated as an adjunct to antimicrobial therapy in patients with chronic urea-splitting urinary tract infections.

Primary Indications

  1. Struvite Stone Prevention: Indicated for patients with infected staghorn calculi who are not surgical candidates.
  2. Post-Surgical Maintenance: Used to prevent the recurrence of struvite stones following the surgical removal of infected calculi.
  3. Refractory UTIs: Targeted use for chronic infections caused by urease-producing organisms where antibiotic therapy alone has failed to prevent stone growth.

Dosage Guidelines

Dosage must be individualized based on clinical presentation and renal function. The standard adult dose is typically 250 mg taken three to four times daily.

  • Initial Dose: 10 mg/kg per day, divided into 3 or 4 doses.
  • Maximum Dose: Generally should not exceed 1.5 grams per day.
  • Renal Impairment: Dosing must be adjusted for patients with a serum creatinine level above 2.0 mg/dL. Reduced frequency or dosage is mandatory to prevent toxicity.

Risks, Side Effects, and Contraindications

Adverse Effects Profile

Lithostat is associated with a range of side effects, some of which are dose-dependent. Patients should be monitored closely during the initiation of therapy.

  • Hematological: Possible hemolytic anemia, leukopenia, or bone marrow suppression.
  • Dermatological: Alopecia, rashes, and localized skin irritation.
  • Gastrointestinal: Nausea, vomiting, abdominal pain, and anorexia.
  • Neurological: Headache, depression, and anxiety.

Contraindications

  • Renal Failure: Use is contraindicated in patients with severe renal impairment (serum creatinine > 2.0 mg/dL) due to the risk of accumulation.
  • Pregnancy/Lactation: Lithostat is classified as Pregnancy Category X. It is teratogenic and must not be used during pregnancy.
  • Hypersensitivity: Known allergy to acetohydroxamic acid or its components.

Drug Interactions

  • Iron Supplements: Lithostat can chelate iron, leading to reduced absorption of both the medication and the iron supplement. A separation of at least 2 hours is recommended.
  • Antacids: May decrease the absorption of acetohydroxamic acid.
  • Alcohol: Increased risk of disulfiram-like reactions or exacerbated neurological side effects.

Pregnancy and Lactation Warnings

Lithostat is strictly contraindicated in women who are pregnant or may become pregnant. Animal studies have shown significant teratogenic effects, including skeletal abnormalities and fetal resorption. If a patient becomes pregnant while taking Lithostat, the medication must be discontinued immediately, and the patient should be counseled on the potential risks to the fetus. It is not known whether the drug is excreted in human milk; however, due to the potential for adverse effects in the infant, breastfeeding is not recommended.


Overdose Management

There is no specific antidote for Lithostat overdose. Management is supportive and symptomatic.
1. Gastric Lavage: Perform if ingestion is recent.
2. Activated Charcoal: Consider for gut decontamination.
3. Monitoring: Closely monitor renal function, complete blood counts (CBC), and neurological status.
4. Dialysis: In cases of severe toxicity or renal failure, hemodialysis may be considered to remove the drug from systemic circulation.


Frequently Asked Questions (FAQ)

1. Is Lithostat an antibiotic?

No, Lithostat is a urease inhibitor. It does not kill bacteria directly but prevents them from producing the enzyme that leads to struvite stone formation.

2. How long must I take Lithostat?

The duration depends on the underlying stone burden and the persistence of the infection. Your urologist will determine the course, often requiring long-term maintenance.

3. Can I take Lithostat with food?

Yes, it can be taken with or without food, but taking it with meals may reduce gastrointestinal irritation.

4. What should I do if I miss a dose?

Take the missed dose as soon as you remember. If it is nearly time for your next dose, skip the missed one. Do not double the dose.

5. Why is Lithostat contraindicated in pregnancy?

It has demonstrated significant teratogenicity in animal studies, meaning it can cause birth defects or fetal harm.

6. Does Lithostat interact with my blood pressure medication?

There are no major clinical interactions with most antihypertensives, but always provide your doctor with a full list of your current medications.

7. How does Lithostat affect my blood counts?

Rarely, it can cause anemia or leukopenia. Regular blood tests (CBC) are recommended during therapy.

8. Will Lithostat dissolve existing stones?

Lithostat is generally used to prevent the growth of new stones or the enlargement of existing ones, rather than dissolving established calculi.

9. What is the main cause of struvite stones?

Struvite stones are caused by urea-splitting bacteria, such as Proteus, which create an alkaline urine environment.

10. When should I contact my doctor while on this medication?

Contact your physician immediately if you experience persistent nausea, severe headaches, unexplained bruising, or signs of an allergic reaction.


Clinical Summary for Healthcare Providers

Lithostat represents a targeted therapeutic approach for the management of complex struvite urolithiasis. While effective, its narrow therapeutic index requires vigilant laboratory monitoring, particularly regarding renal function and hematologic status. Clinicians should prioritize patient education regarding compliance and the avoidance of concurrent iron supplementation to ensure the success of the therapeutic regimen. In the context of multidisciplinary care, Lithostat should be integrated into a comprehensive strategy that includes aggressive hydration, dietary modifications, and appropriate antimicrobial therapy.

Share this guide: